Scale-Up Issues in Parenterals MCQs With Answer

Scale-Up Issues in Parenterals MCQs With Answer

This quiz collection focuses on the critical scale-up and technology transfer challenges specific to parenteral products. It covers sterility assurance, heat and mass transfer, filtration and container-closure integrity, lyophilization, aseptic processing validation (media fills), cleaning/CIP dynamics, and regulatory expectations during technology transfer. Each question is designed for M.Pharm students to deepen understanding of process parameters, dimensionless similarity, validation requirements, and risk mitigation when moving from lab to pilot and commercial scale. Use these MCQs for revision or group discussion to reinforce practical decision-making and troubleshooting during scale-up of injectable formulations.

Q1. What is the single most critical challenge when scaling up aseptic fill-finish operations for parenteral products?

• Maintaining sterile processing conditions and preventing contamination during increased throughput
• Matching pH and osmolarity profiles of the formulation
• Ensuring identical color and clarity of the product
• Reducing manufacturing costs per unit

Correct Answer: Maintaining sterile processing conditions and preventing contamination during increased throughput

Q2. Which dimensionless number is most commonly used to achieve dynamic similarity during scale-up of mixing processes?

• Reynolds number
• Prandtl number
• Fourier number
• Biot number

Correct Answer: Reynolds number

Q3. During lyophilization scale-up for parenteral solutions, which parameter strongly influences primary drying time and cycle transferability?

• Shelf heat transfer coefficient (Kv)
• Final product pH
• Container color
• Initial fill temperature only

Correct Answer: Shelf heat transfer coefficient (Kv)

Q4. When scaling up sterile filtration of a parenteral solution, which attribute must be validated to ensure sterility is maintained?

• Filter integrity and bacterial retention
• Filter color
• Filter brand name only
• Filter packaging artwork

Correct Answer: Filter integrity and bacterial retention

Q5. Which factor primarily determines microbial inactivation during moist heat sterilization in parenteral processing?

• Temperature-time profile applied to the product
• Ambient room humidity during sterilization
• Container external color
• The operator’s experience level

Correct Answer: Temperature-time profile applied to the product

Q6. For scale-up of agitation in large stainless-steel vessels preparing parenteral solutions, which scale-up rule is most appropriate for maintaining mixing performance for a Newtonian liquid?

• Maintain constant power per unit volume (P/V)
• Maintain constant impeller diameter only
• Maintain constant fill height without regard to power
• Maintain identical motor brand across scales

Correct Answer: Maintain constant power per unit volume (P/V)

Q7. In aseptic processing validation, what is a media fill (process simulation) intended to demonstrate?

• The aseptic process can produce sterile product under routine operating conditions
• The product’s long-term chemical stability
• Compatibility of packaging print labels
• Electrical safety of the fill line

Correct Answer: The aseptic process can produce sterile product under routine operating conditions

Q8. Increasing batch size of a parenteral solution often increases the risk of which operational issue?

• Longer hold times leading to increased contamination or degradation risk
• Lower pH of the bulk solution automatically
• Automatic improvement in particulate levels
• Reduction in regulatory expectations

Correct Answer: Longer hold times leading to increased contamination or degradation risk

Q9. When scaling up thermal processing of viscous parenteral fluids, the most effective way to improve heat transfer is to:

• Increase heat transfer surface area or agitation to enhance convection
• Reduce product viscosity by adding solvent without validation
• Change the active pharmaceutical ingredient
• Use larger containers with the same jacket design

Correct Answer: Increase heat transfer surface area or agitation to enhance convection

Q10. Which container-closure integrity test is considered most sensitive and non-destructive for parenteral sterile products at commercial scale?

• Helium leak detection (vacuum decay/helium mass spectrometry)
• Dye ingress immersion test
• Visual inspection only
• pH indicator strip test

Correct Answer: Helium leak detection (vacuum decay/helium mass spectrometry)

Q11. For depyrogenation of glassware used for parenteral containers, which method is standard and effective at production scale?

• Dry heat depyrogenation at validated time-temperature (e.g., 250°C for specified minutes)
• Standard steam autoclaving at 121°C for 15 minutes
• Washing with potable water only
• Ultraviolet irradiation of the outside surface

Correct Answer: Dry heat depyrogenation at validated time-temperature (e.g., 250°C for specified minutes)

Q12. In scale-up of sterile filtration, which operational parameter is essential to control to avoid fouling and ensure throughput?

• Flux and transmembrane pressure (TMP)
• Filter package color
• Operator shoe size
• Batch numbering system

Correct Answer: Flux and transmembrane pressure (TMP)

Q13. What is the required ISO classification (Grade) for the critical aseptic filling zone where open product and sterile critical operations occur?

• ISO 5 (Grade A)
• ISO 8 (Grade D)
• ISO 7 (Grade B)
• ISO 9 (non-classified)

Correct Answer: ISO 5 (Grade A)

Q14. The primary objective of technology transfer for parenteral products is to:

• Reproduce product quality and critical process performance at the receiving site
• Reduce staff at the receiving site
• Change the product formulation to cut costs
• Replace all analytical methods with local variants without qualification

Correct Answer: Reproduce product quality and critical process performance at the receiving site

Q15. When scaling up a freeze-drying cycle, why must primary drying temperature be carefully controlled relative to the product’s critical temperatures?

• To avoid product collapse by staying below collapse temperature while maximizing sublimation rate
• To ensure the product changes color uniformly
• To speed up secondary packaging rather than drying
• Because higher temperatures always improve sterility

Correct Answer: To avoid product collapse by staying below collapse temperature while maximizing sublimation rate

Q16. During scale-up of CIP (clean-in-place) for parenteral manufacturing, which factor often changes and impacts cleaning efficiency the most?

• Flow regime (laminar versus turbulent) affecting shear and cleaning action
• Active pharmaceutical ingredient molecular weight only
• Label design on the cleaning chemical
• Operator glove color

Correct Answer: Flow regime (laminar versus turbulent) affecting shear and cleaning action

Q17. What Sterility Assurance Level (SAL) is typically targeted for terminal sterilization processes for parenterals?

• 10^-6
• 10^-3
• 10^-9
• 10^0

Correct Answer: 10^-6

Q18. In media fill validation for an aseptic line, why are worst-case conditions used?

• To challenge and demonstrate the robustness of the aseptic process under the most demanding operating conditions
• To reduce the number of validation runs required
• To guarantee 100% product sterility regardless of controls
• To avoid cleaning between runs

Correct Answer: To challenge and demonstrate the robustness of the aseptic process under the most demanding operating conditions

Q19. Which product property most directly affects filter selection and sterilizing filter performance when scaling up parenteral filtration?

• Solution viscosity and particulate load
• Bottle cap color
• Operator height
• Manufacturing site zip code

Correct Answer: Solution viscosity and particulate load

Q20. Which document is essential during technology transfer to ensure consistent commercial manufacture of a parenteral product?

• A comprehensive technology transfer protocol including critical process parameters, acceptance criteria, and analytical methods
• A marketing brochure for the product
• A generic equipment procurement list without process details
• An informal verbal agreement between sites

Correct Answer: A comprehensive technology transfer protocol including critical process parameters, acceptance criteria, and analytical methods

Download